Knobbe/Martens: Intellectual Property Law

Biosimilars

Biosimilars

Our extensive Hatch-Waxman litigation practice and successful practice in post-grant PTO proceedings, combined with our deep technical expertise in biotechnology, uniquely positions us to develop and implement effective IP strategies for biosimilars. This industry-specific expertise is backed by one of the largest and most experienced biotechnology groups in IP law, with more than 75 attorneys and scientists representing clients in all stages of their business and technology development, as well a talented litigation group adept in all aspects of biotechnology IP law.

Our attorneys have the bench strength to help you successfully navigate the biosimilars pathway.

  • Up-to-date knowledge of biosimilars legislation
  • IP litigators with numerous trial and appellate successes
  • Extensive Hatch-Waxman litigation experience
  • Successful Post-Grant PTO practice on behalf of patent owners and petitioners
  • Over 20 attorneys with PhD’s in the life sciences
  • Extensive experience in biologics patent prosecution
  • Licensing and other transactional experience related to biologics

Count on our deep expertise across a spectrum of technologies.

  • Antibodies & Immunology
  • Biological Manufacturing of Chemicals
  • Biologics
  • Diagnostic Tools
  • Peptides
  • Personalized Medicine
  • Research Tools & Reagents
  • Stem Cells & Regenerative Medicine
  • Therapeutics
  • Vaccines
Attorney Finder